Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: LON:VER
- CUSIP: N/A
- Web: www.vernalis.com
- Market Cap: £84.22 million
- Outstanding Shares: 526,351,000
- 50 Day Moving Avg: GBX 16.48
- 200 Day Moving Avg: GBX 19.38
- 52 Week Range: GBX 14.62 - GBX 45.12
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £11.87 million
- Price / Sales: 7.09
- Book Value: GBX 0.18 per share
- Price / Book: 0.89
- EBIDTA: ($28,070,000.00)
- Net Margins: -198.87%
- Return on Equity: -22.58%
- Return on Assets: -20.11%
- Average Volume: 141,963 shs.
Frequently Asked Questions for Vernalis plc (LON:VER)
What is Vernalis plc's stock symbol?
Vernalis plc trades on the London Stock Exchange (LON) under the ticker symbol "VER."
How were Vernalis plc's earnings last quarter?
Vernalis plc (LON:VER) posted its quarterly earnings results on Tuesday, September, 12th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($4.50) by $0.40. The firm earned $20.79 million during the quarter. Vernalis plc had a negative return on equity of 22.58% and a negative net margin of 198.87%. View Vernalis plc's Earnings History.
Where is Vernalis plc's stock going? Where will Vernalis plc's stock price be in 2017?
6 analysts have issued 12 month price targets for Vernalis plc's stock. Their predictions range from GBX 21 to GBX 88. On average, they anticipate Vernalis plc's stock price to reach GBX 39.40 in the next twelve months. View Analyst Ratings for Vernalis plc.
Who are some of Vernalis plc's key competitors?
Some companies that are related to Vernalis plc include Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), CTI BioPharma Corp. (CTIC), Pluristem Therapeutics (PSTI), Regulus Therapeutics (RGLS), Novelion Therapeutics (NVLN), GTx (GTXI), Oramed Pharmaceuticals (ORMP), Silence Therapeutics plc (SLN), Matinas BioPharma Holdings (MTNB), CASI Pharmaceuticals (CASI), BioLineRx (BLRX), Eiger BioPharmaceuticals (EIGR), Palatin Technologies (PTN), Tissue Regenix Group PLC (TRX), aTyr Pharma (LIFE) and Zynerba Pharmaceuticals (ZYNE).
Who are Vernalis plc's key executives?
Vernalis plc's management team includes the folowing people:
- Ian R. Garland, Chief Executive Officer, Executive Director
- David Mackney, Chief Financial Officer, Executive Director
- Kevin Kissane, Company Secretary
- Peter J. Fellner, Non-Executive Chairman of the Board
- Ian David Gilham Ph.D., Non-Executive Director
- Lisa Amster Schoenberg, Non-Executive Director
- Carol C. Ferguson, Senior Independent Non-Executive Director
- Nigel Sheail, Non-Executive Independent Director
How do I buy Vernalis plc stock?
Shares of Vernalis plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Vernalis plc's stock price today?
MarketBeat Community Rating for Vernalis plc (LON VER)MarketBeat's community ratings are surveys of what our community members think about Vernalis plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Vernalis plc stock can currently be purchased for approximately GBX 16.
Consensus Ratings for Vernalis plc (LON:VER) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||GBX 39.40|
Analysts' Ratings History for Vernalis plc (LON:VER)
(Data available from 9/20/2015 forward)
|8/7/2017||Panmure Gordon||Reiterated Rating||Hold||GBX 31|
|8/7/2017||Stifel Nicolaus||Lower Price Target||Hold||GBX 24 -> GBX 21|
|8/7/2017||RX Securities||Reiterated Rating||Buy|
|8/7/2017||N+1 Singer||Reiterated Rating||Hold||GBX 28|
|4/21/2017||Numis Securities Ltd||Reiterated Rating||Add||GBX 29|
|2/14/2017||Canaccord Genuity||Reiterated Rating||Buy||GBX 88|
|12/21/2016||Shore Capital||Reiterated Rating||house stock|
Earnings History for Vernalis plc (LON:VER)Earnings History by Quarter for Vernalis plc (LON VER)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/12/2017||Y 2017||GBX (4.50)||GBX (4.10)||GBX 2,079 million||View||N/A|
Earnings Estimates for Vernalis plc (LON:VER)
Current Year EPS Consensus Estimate: $-5.57 EPS
Dividend History for Vernalis plc (LON:VER)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vernalis plc (LON:VER)Insider Trades by Quarter for Vernalis plc (LON:VER)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/12/2016||David Mackney||Insider||Sell||27,233||GBX 39||£10,620.87|
|9/30/2016||Carol Ferguson||Insider||Buy||28,000||GBX 41||£11,480|
|5/5/2015||Nigel Sheail||Insider||Buy||84,000||GBX 59.90||£50,316|
Headline Trends for Vernalis plc (LON:VER)
Latest Headlines for Vernalis plc (LON:VER)
Vernalis plc (VER) Chart for Wednesday, September, 20, 2017